ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "risk factors"

  • Abstract Number: 1646 • ACR Convergence 2020

    Use of Prescription Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in Adults with Hip/Knee Osteoarthritis (OA) at Increased Risk for NSAID-related Adverse Events

    Jayeshkumar Patel1, Wenhui Wei2, Raveendhara Bannuru3, Ravi Iyer4, Nazneen Fatima Shaikh1, Traci LeMasters1, Chibuzo Iloabuchi1, Degang Wang2 and Usha Sambamoorthi1, 1West Virginia University School of Pharmacy, Morgantown, WV, 2Regeneron Pharmaceuticals, Tarrytown, NY, 3Tufts Medical Center, Boston, MA, 4Teva Pharmaceutical Industries, West Chester, PA

    Background/Purpose: NSAIDs are commonly used for OA pain, but the benefits of pain relief must be carefully weighed against the potential risk for gastrointestinal (GI),…
  • Abstract Number: 0040 • ACR Convergence 2020

    Whole Blood RNA Expression in Clinically Suspected Arthralgia Patients Shows a Potential Value in Prediction of Inflammatory Arthritis

    Ellis Niemantsverdriet1, Erik van den Akker1, Debbie Boeters1, Susan van den Eeden1, Annemieke Geluk1 and Annette van der Helm - van Mil2, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA)-patients have differently expressed genes involved in cytokine/chemokine-mediated immunity compared to healthy controls, which are changed years before RA-diagnosis. It is unclear,…
  • Abstract Number: 0635 • ACR Convergence 2020

    Hydroxychloroquine Is Not Associated with Reduced Influenza Admissions in Rheumatoid Arthritis Patients

    Bonnia Liu1, Victor Yang2, Christopher McMaster3, Russell Buchanan4, Albert Frauman5 and David Liew6, 1Austin Health, Heidelberg, Victoria, Australia, Macleod, Victoria, Australia, 2Austin Health, Heidelberg, Victoria, Australia, Glen Waverley, Victoria, Australia, 3Austin Health, Melbourne, Victoria, Australia, Pascoe Vale South, Victoria, Australia, 4Austin Health, Melbourne, Victoria, Australia, Heidelberg, Melbourne, Victoria, Australia, 5Austin Health, Melbourne, Victoria, Australia, Melbourne, Victoria, Australia, 6Austin Health, Melbourne, Victoria, Australia, Heidelberg, Victoria, Australia

    Background/Purpose: Hydroxychloroquine (HCQ) is commonly used as a disease-modifying anti-rheumatic drug (DMARD) for patients with rheumatoid arthritis (RA). HCQ has previously been the subject of…
  • Abstract Number: 1082 • ACR Convergence 2020

    The Presence of Anti-Jo1, anti-PL7, And/or anti-MDA5 Antibodies in Idiopathic Inflammatory Myopathy Confers an Increased Risk of a Significant Restrictive Pulmonary Defect

    Dmitriy Cherny1 and Carrie Richardson1, 1Rush University Medical Center, Chicago, IL

    Background/Purpose: A subset of patients with idiopathic inflammatory myopathy develop significant restrictive lung disease, although risk factors for this are poorly defined. Autoantibodies may be…
  • Abstract Number: 1660 • ACR Convergence 2020

    Sleep Disturbance and Pain Severity and Multi-site Pain: A Prospective 10.7-year Follow-up Study

    Feng Pan1, Jing Tian1, Flavia Cicuttini2 and Graeme Jones1, 1University of Tasmania Menzies Institute for Medical Research, Hobart, Tasmania, Australia, 2Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

    Background/Purpose: Sleep disturbance is often comorbid with chronic pain disorders, with emerging evidence suggesting a stronger effect of sleep disturbance on pain than vice versa;…
  • Abstract Number: 0089 • ACR Convergence 2020

    The Risk Factors of Recurrence in Relapsing Polychondritis; A Study of 41 Cases

    Tsuneyasu Yoshida1, Hajime Yoshifuji2, Mirei Shirakashi1, Koji Kitagori1, Shuji Akizuki2, Ran Nakashima1, Kosaku Murakami1, Motomu Hashimoto3, Masao Tanaka3 and Koichiro Ohmura1, 1Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Kyoto, Japan, 2Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, Kyoto, Japan, 3Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan

    Background/Purpose: Relapsing polychondritis (RP) is a rare disease which causes inflammation in systemic cartilages. Although glucocorticoids (GC) and immunosuppressive drugs (IS) have been used, the…
  • Abstract Number: 0641 • ACR Convergence 2020

    Cohort of Rheumatic Patients Treated with Rituximab and COVID-19: Does Rituximab Treatment Increases the Severity of SARS-COV2 Infection?

    Antía García-Fernández1, Fernando López-Gutiérrez1, Jesús Loarce-Martos1, Ivan Del Bosque-Granero2, Laura Calvo-Sanz1, Boris Blanco-Cáceres1, Cristina Pijoan-Moratalla1, Lourdes Villalobos-Sánchez3, Javier Bachiller-Corral1 and Mónica Vázquez1, 1Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, 2Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, 3Rheumatology, Hospital Universitario Ramón y Cajal, Madrid

    Background/Purpose: There are very few studies reporting COVID-19 in patients with rheumatic diseases, without clear evidence supporting more frequent or severe disease in these patients.…
  • Abstract Number: 1188 • ACR Convergence 2020

    Serum Anti-malondialdehyde-acetaldehyde IgA Antibody Concentration Improves Prediction of Coronary Atherosclerosis Beyond Traditional Risk Factors in Patients with Rheumatoid Arthritis

    Hannah Lomzenski1, Geoffrey Thiele2, Michael Duryee2, Sheau-Chiann Chen1, Fei Ye1, Ted Mikuls2, C. Michael Stein1 and Michelle Ormseth1, 1Vanderbilt University Medical Center, Nashville, TN, 2University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Patients with rheumatoid arthritis (RA) have increased cardiovascular disease (CVD) independent of traditional risk factors. Oxidative stress is increased in patients with RA and…
  • Abstract Number: 1720 • ACR Convergence 2020

    Factors Associated with an Increased Risk of Imminent Rheumatoid Arthritis in ACPA+ Individuals

    Hyoun-Ah Kim1, Ryan Peterson2, Gary Firestein3, David Boyle4, Jane Buckner5, Sylvia Posso6, Eddie James5, William Robinson7, Jaron Arbet2, LauraKay Moss8, Roger Gilmore8, Lindsay Hartje8, Saman Barzideh8, Jennifer Seifert9, Navin Rao10, Frédéric Baribaud11, Sunil Nagpal12, Alyssa Johnson13, V Michael Holers14 and Kevin D. Deane15, 1University of Colorado Anschutz Medical Campus and Ajou University School of Medicine, Aurora, CO, 2Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, 3University of California, San Diego, La Jolla, CA, 4UC San Diego, San Diego, CA, 5Center for Translational Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, 6Benaroya Research Institute at Virginia Mason, Seattle, WA, 7Stanford University, Palo Alto, CA, 8University of Colorado Anschutz Medical Campus, Aurora, CO, 9Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Littleton, CO, 10Janssen R&D, Spring House, PA, 11Janssen Research & Development, LLC, Spring House, PA, 12Janssen Reserach and Development, Spring House, PA, 13Janssen Research and Development, Spring House, PA, 14Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado, 152 Division of Rheumatology, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA, Colorado

    Background/Purpose: Individuals at high-risk for future rheumatoid arthritis (RA) may be identified by screening for circulating RA-related autoantibodies including antibodies to citrullinated protein antigens (ACPA).…
  • Abstract Number: 0120 • ACR Convergence 2020

    Risk of Fracture in Patients with Different Glucocorticoid Requiring Diseases

    Giovanni Adami1, Angelo Fassio2, Alessandro Giollo2, Luca Idolazzi2, Ombretta Viapiana1, Davide Gatti2 and Maurizio Rossini2, 1University of Verona, Verona, Italy, 2Rheumatology Unit, University of Verona, Verona, Italy

    Background/Purpose: The aim of the present work is to determine the fracture risk associated with glucocorticoids requiring diseasesMethods: We conducted a retrospective analysis of a nation-wide…
  • Abstract Number: 0662 • ACR Convergence 2020

    Cause-Specific Mortality in Patients with Gout in the Veteran’s Health Administration: A Matched Cohort Study

    Lindsay Helget1, Bryant England1, Punyasha Roul1, Harlan Sayles1, Alison Petro1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Gout is the most common type of inflammatory arthritis, with a prevalence in the Veteran’s Health Administration (VHA) of nearly 6%.   While gout flares…
  • Abstract Number: 1262 • ACR Convergence 2020

    Single LAC Positivity versus Double and Triple Positivity for Thrombosis in SLE

    Selcan Demir1, Jessica Li2, Laurence Magder3 and Michelle Petri4, 1Hacettepe University Faculty of Medicine, Ankara, Ankara, Turkey, 2Johns Hopkins University, Baltimore, MD, 3University of Maryland, Baltimore, Baltimore, MD, 4Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose:Antiphospholipid syndrome (APS) is classified as the development of venous and/or arterial thromboses, and pregnancy morbidity, in the presence of antiphospholipid antibodies (aPL); lupus anticoagulant,…
  • Abstract Number: 1751 • ACR Convergence 2020

    Forecasting Healthcare Utilization in Rheumatoid Arthritis: A Machine Learning Predictive Model of Emergency Department Visits and Prednisone Initiation in a Single Tertiary Academic Center

    Elston He1, Eli Cornblath2, Pratyusha Yalamanchi3, Alexis Ogdie2, Joshua Baker2 and Michael George2, 1Synovium, Inc., Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Michigan Medicine, Ann Arbor, MI

    Background/Purpose: Despite recent advances in therapy, 42% of patients with rheumatoid arthritis (RA) nationwide had moderate or high disease activity at their most recent visit.…
  • Abstract Number: 0129 • ACR Convergence 2020

    Glucocorticoid-Induced Osteoporosis in Patients with Chronic Inflammatory Rheumatic Diseases: A Multivariate Linear Regression Analysis Identifying Factors Affecting Bone Mineral Density

    Edgar Wiebe1, Desiree Freier1, Dörte Huscher2, Sandra Hermann1, Robert Biesen3 and Frank Buttgereit4, 1Charité University Medicine Berlin, Dep. of Rheumatology and Clinical Immunology, Berlin, Germany, 2Charité University Medicine Berlin, Dep. of Biometry and Clinical Epidemiology, Berlin, Germany, 3Charité University Medicine, Dep. of Rheumatology and Clinical Immunology, Berlin, 4Charité University Medicine, Berlin, Germany

    Background/Purpose: Rheumatic diseases are associated with increased systemic bone loss and fracture risk related to chronic inflammation, disease-specific, general and demographic risk factors as well…
  • Abstract Number: 0671 • ACR Convergence 2020

    Structured Cardiovascular Assessment in Gout Incorporating Carotid Ultrasound: Analysis of Subsequent Events in the Follow-Up

    Mar Monzó1, Neus Quilis2, Laura Ranieri2, Alejandro San-Martín3 and Mariano Andrés4, 1Universidad Miguel Hernández, Alicante, Spain, 2Hospital Universitario del Vinalopó, Alicante, Spain, 3Clínica HLA Vistahermosa, Alicante, Spain, 4Hospital General Universitario de Alicante-ISABIAL and Universidad Miguel Hernández de Elche, Alicante, Spain

    Background/Purpose: Gout is an independent cardiovascular (CV) risk factor. This excess of morbidity and mortality requires optimal management, especially in high-risk individuals. Therefore, the inclusion…
  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology